Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Desi...
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background and objective:
Atherogenic lipid parameters in patients with mixed dyslipidaemia have been demonstrated to increase atherosclerotic coronary heart disease (CHD) risk. Clinical studies have shown that HMG-CoA reductase inhibitor (statin) and fibric acid derivative (fibrate) combination therapy is effective at improving multiple lipid a...
Alternative Titles
Full title
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_224991768
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_224991768
Other Identifiers
ISSN
1173-2563
E-ISSN
1179-1918
DOI
10.2165/00044011-200828100-00003
